{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:14:40Z","timestamp":1775200480148,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"LS has received institutional grants from Amgen and Philips and served as site PI for V-INITIATE trial."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11883-024-01218-2","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T08:01:59Z","timestamp":1717401719000},"page":"367-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference"],"prefix":"10.1007","volume":"26","author":[{"given":"Kartik","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat","family":"Rawlley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Meloche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"Hermel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Dalakoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"6","key":"1218_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11883-023-01103-4","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Balachandran I, Foy J, et al. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023;25(6):309\u201321. https:\/\/doi.org\/10.1007\/s11883-023-01103-4.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1218_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11883-022-01079-7","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Hirsch JR, Kalsi J, Patel V, Gad MM, Virani SS. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023;25(1):31\u201341. https:\/\/doi.org\/10.1007\/s11883-022-01079-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1218_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000919","volume":"35","author":"JL Katzmann","year":"2024","unstructured":"Katzmann JL, Laufs U. PCSK9-directed therapies: an update. Curr Opin Lipidol. 2024;35(3):117\u201325. https:\/\/doi.org\/10.1097\/MOL.0000000000000919.","journal-title":"Curr Opin Lipidol."},{"key":"1218_CR4","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Bergmark Brian A., Marston Nicholas A., Prohaska Thomas A., et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2402309","DOI":"10.1056\/NEJMoa2402309"},{"issue":"6","key":"1218_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11886-022-01694-5","volume":"24","author":"NS Maitra","year":"2022","unstructured":"Maitra NS, Mahtta D, Navaneethan S, et al. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022;24(6):689\u201398. https:\/\/doi.org\/10.1007\/s11886-022-01694-5.","journal-title":"Curr Cardiol Rep"},{"issue":"14","key":"1218_CR6","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/eurjpc\/zwac103","volume":"29","author":"MD Chobufo","year":"2022","unstructured":"Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017\u20132020. Eur J Prev Cardiol. 2022;29(14):1830\u20138. https:\/\/doi.org\/10.1093\/eurjpc\/zwac103.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1218_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11886-023-01861-2","volume":"25","author":"A Mehta","year":"2023","unstructured":"Mehta A, Dixon DL, Saeed A, et al. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? Curr Cardiol Rep. 2023;25(5):423\u201330. https:\/\/doi.org\/10.1007\/s11886-023-01861-2.","journal-title":"Curr Cardiol Rep"},{"key":"1218_CR8","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Nissen SE, Hutchinson HG, Wolski K, et al. A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication. J Am Coll Cardiol. 0(0). https:\/\/doi.org\/10.1016\/j.jacc.2024.03.388","DOI":"10.1016\/j.jacc.2024.03.388"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","volume":"256","author":"JL Januzzi","year":"2023","unstructured":"Januzzi JL, Butler J, Del Prato S, et al. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. 2023;256:25\u201336. https:\/\/doi.org\/10.1016\/j.ahj.2022.11.003.","journal-title":"Am Heart J"},{"issue":"1","key":"1218_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12933-024-02135-z","volume":"23","author":"JL Januzzi","year":"2024","unstructured":"Januzzi JL, Del Prato S, Rosenstock J, et al. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. Cardiovasc Diabetol. 2024;23(1):49. https:\/\/doi.org\/10.1186\/s12933-024-02135-z.","journal-title":"Cardiovasc Diabetol"},{"key":"1218_CR11","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Januzzi JL, Butler J, Del PS, et al. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy. J Am Coll Cardiol. 0(0). https:\/\/doi.org\/10.1016\/j.jacc.2024.03.380","DOI":"10.1016\/j.jacc.2024.03.380"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"774418","DOI":"10.3389\/fcvm.2021.774418","volume":"8","author":"JJ Lee","year":"2021","unstructured":"Lee JJ, Chi G, Fitzgerald C, et al. Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;8:774418. https:\/\/doi.org\/10.3389\/fcvm.2021.774418.","journal-title":"Front Cardiovasc Med"},{"key":"1218_CR13","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Gibson C. Michael, Duffy Danielle, Korjian Serge, et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2400969","DOI":"10.1056\/NEJMoa2400969"},{"key":"1218_CR14","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Koren MJ, Rodriguez F, East C, et al. An Inclisiran First Strategy vs Usual Care in Patients with Atherosclerosis. J Am Coll Cardiol. 0(0). https:\/\/doi.org\/10.1016\/j.jacc.2024.03.382","DOI":"10.1016\/j.jacc.2024.03.382"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2023.05.017","volume":"264","author":"JM Ahn","year":"2023","unstructured":"Ahn JM, Kang DY, Lee PH, et al. Preventive PCI or medical therapy alone for vulnerable atherosclerotic coronary plaque: Rationale and design of the randomized, controlled PREVENT trial. Am Heart J. 2023;264:83\u201396. https:\/\/doi.org\/10.1016\/j.ahj.2023.05.017.","journal-title":"Am Heart J"},{"key":"1218_CR16","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. The Lancet. 2024;0(0). https:\/\/doi.org\/10.1016\/S0140-6736(24)00413-6","DOI":"10.1016\/S0140-6736(24)00413-6"},{"key":"1218_CR17","doi-asserted-by":"publisher","unstructured":"\u2022 Stone GW, Maehara A, Ali ZA, et al. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. J Am Coll Cardiol. 2020;76(20):2289\u2013301. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.547.","DOI":"10.1016\/j.jacc.2020.09.547"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01218-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01218-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01218-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T09:58:23Z","timestamp":1720605503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01218-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01218-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"17 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LS has received institutional grants from Amgen and Philips and served as site PI for V-INITIATE trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}